[weekly] the first cancer stem cell targeted drug, once again declared as a new chemical class 1 drug

This week (2017.01.03-2017.01.06), 57 drugs (calculated by acceptance number, the same below) entered the CDE evaluation center, including 4 traditional Chinese medicines, 42 chemical drugs and 11 biological products Key introduction: 1 Xy0206 and its tablets (acceptance No.: cxhl1600270-72) are chemical class 1 new drugs declared by Shijiazhuang Yiling Pharmaceutical Co., Ltd., which have been undertaken by CDE recently According to data query, xy0206 is the first chemical class 1 new drug in Yiling pharmaceutical industry At present, the queue serial number is more than 100, and the indication information of this product has not been found yet 2 Gb201 (acceptance No.: jxhl1600156) has been applied for the fourth time by us Qiangxin Biotechnology Co., Ltd this time, it is applied as a chemical class 1 imported drug and is under review Gb201 is one of the major R & D projects of strong new technology and the first cancer stem cell targeted drug in the world The clinical results show that gb201 has good safety, pharmacokinetic characteristics and potential broad-spectrum anti-cancer effect, among which it has exciting potential therapeutic effect on many kinds of cancer Gb201 ranks first among the "top ten global anti-cancer drugs in clinical research and development stage in 2012" selected by the famous fierce biotechnology organization 3 Jiangsu Enhua Pharmaceutical Co., Ltd has the right to develop and sell nvx-408, the exclusive product under research of NuVox pharma and LLC in China NuVox is committed to developing oxygen therapy based on ddfp for the treatment of human diseases It has been proved that oxygen therapy is feasible in the treatment of radiation-resistant cancer, stroke, hemorrhagic shock, surgical bleeding, myocardial infarction, traumatic brain injury and retinopathy Nvx-408 is a kind of perfluoropentane emulsion, which is suitable for the treatment of perioperative blood loss and hemorrhagic shock It can partly replace the function of blood 4 The clinical approval document of prosafel submitted by Guoyao Yixin Pharmaceutical Co., Ltd was obtained in 2015, and it is currently in the process of recruitment, clinical registration No.: ctr20161069 Prozac is suitable for non Hodgkin's lymphoma (NHL) A novel CXCR4 chemokine receptor blocker has been shown to increase the number of stem cells in the blood circulation of patients with NHL and mm The purpose of this test is to evaluate whether the mobilization of NHL patients with recombinant human granulocyte colony stimulating factor (G-CSF) + Prozac injection is easier to achieve the target collection quantity of CD34 + cells ≥ 5 × 106 / kg (single collection ≤ 4 days) than that with G-CSF + placebo, and evaluate its safety; target number of participants: 100 Note: This article is the original manuscript of the author of yaozhi.com, welcome to reprint, please indicate the source and author when reprint, thank you!